GSK has acquired GlycoVaxyn.
Since forming a scientific collaboration in 2012, GSK has held a minority stake in GlycoVaxyn and has now acquired the remaining shares for US $190 million (approximately £124 million) in cash to take full ownership of the company.
GlycoVaxyn has developed an innovative biological conjugation platform technology which has the potential to play an important role in the development of new prophylactic and therapeutic vaccines for a range of bacterial diseases.
|Searching for more deal information? Current Partnering offers the following options:|
This proprietary technology also has the potential to enable GSK to develop a simplified conjugate vaccine manufacturing process.
GSK will additionally acquire a small number of early stage vaccines in development against bacterial infections such as pneumonia, Pseudomonas, Staphylococcus aureus and Shigellosis, supplementing the company’s existing vaccines pipeline.
For further deal information visit Current Agreements (subscription required)
Scorecard: Top partnering deals by value in 2015
View: Top biotech companies